ABSTRACT
GPR55 is an orphan G-protein coupled receptor involved in various pathophysiological conditions. However, there are only a few noncannabinoid GPR55 ligands reported so far. The lack of potent and selective GPR55 ligands precludes a deep exploration of this receptor. The studies presented here focused on a thienopyrimidine scaffold based on the GPR55 antagonist ML192, previously discovered by high-throughput screening. The GPR55 activities of the new synthesized compounds were assessed using ß-arrestin recruitment assays in Chinese hamster ovary cells overexpressing human GPR55. Some derivatives were identified as GPR55 antagonists with functional efficacy and selectivity versus CB1 and CB2 cannabinoid receptors.
ABSTRACT
Cannabidiol (CBD) is one of the most abundant components isolated from Cannabis sativa. However, CBD is a nonpsychotropic phytocannabinoid. In the last decade, there has been a growing interest in its therapeutic effects. This is why this natural product represents a lead structure for the development of new cannabinoid compounds. Even though chemistry of CBD has been explored for more than 30 years, the synthesis of only a few derivatives has been described. This chapter first reviews the synthetic methods for the preparation of CBD and derivatives. Then, it describes procedures for the synthesis of N-heterocyclic derivatives of CBD with, in particular, the preparation and structural characterization of 5-alkyl-2-(1H-pyrazol-3-yl)benzene-1,3-diol.